MX2020012014A - Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. - Google Patents

Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Info

Publication number
MX2020012014A
MX2020012014A MX2020012014A MX2020012014A MX2020012014A MX 2020012014 A MX2020012014 A MX 2020012014A MX 2020012014 A MX2020012014 A MX 2020012014A MX 2020012014 A MX2020012014 A MX 2020012014A MX 2020012014 A MX2020012014 A MX 2020012014A
Authority
MX
Mexico
Prior art keywords
derivatives
ocular hypertension
treating glaucoma
prostaglandin
conjugates
Prior art date
Application number
MX2020012014A
Other languages
English (en)
Inventor
David Ellis
Lukas Scheibler
Najam Sharif
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020012014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MX2020012014A publication Critical patent/MX2020012014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/02—Preparation of esters of nitric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C203/00—Esters of nitric or nitrous acid
    • C07C203/02—Esters of nitric acid
    • C07C203/08—Esters of nitric acid having nitrate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/08—Azoxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer conjugados y derivados de prostaglandina y los métodos para su uso para tratar el glaucoma y/o presión inferior intraocular. Adicionalmente, las composiciones farmacéuticas oftálmicas útiles en el tratamiento de enfermedades oculares tales como el glaucoma y la presión intraocular elevada se dan a conocer. Tales composiciones comprenden una cantidad eficaz de conjugados o derivados de prostaglandina de la presente invención.
MX2020012014A 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. MX2020012014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064193P 2014-10-15 2014-10-15
PCT/US2015/055766 WO2016061370A1 (en) 2014-10-15 2015-10-15 Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
MX2020012014A true MX2020012014A (es) 2022-04-19

Family

ID=54478216

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2017004809A MX2017004809A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020012012A MX2020012012A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020012014A MX2020012014A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020012011A MX2020012011A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2019011925A MX2019011925A (es) 2014-10-15 2017-04-11 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017004809A MX2017004809A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020012012A MX2020012012A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020012011A MX2020012011A (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2019011925A MX2019011925A (es) 2014-10-15 2017-04-11 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Country Status (12)

Country Link
US (2) US9604949B2 (es)
EP (1) EP3206693B1 (es)
JP (2) JP6654757B2 (es)
KR (1) KR20170066427A (es)
CN (2) CN107106573A (es)
AR (1) AR102283A1 (es)
AU (1) AU2015332447B2 (es)
BR (1) BR112017007095B1 (es)
CA (1) CA2964364A1 (es)
MX (5) MX2017004809A (es)
RU (1) RU2712221C2 (es)
WO (1) WO2016061370A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
KR102282716B1 (ko) * 2020-02-07 2021-07-29 포항공과대학교 산학협력단 일산화질소 공여체를 포함하는 뇌-혈관 장벽 투과성을 증가시키는데 사용하기 위한 조성물 및 그의 용도
WO2021220061A2 (en) * 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002124A1 (en) * 1988-08-23 1990-03-08 Aktiebolaget Hässle Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
US7176238B1 (en) * 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use
DK1704141T3 (en) * 2004-01-05 2016-05-02 Nicox Sa Prostaglandin nitrooxyderivatives
CA2613748A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Prostaglandin derivatives
WO2007044963A2 (en) * 2005-10-13 2007-04-19 Novokin Biotech Inc. Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions
AU2009236356A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
EP2496553A4 (en) * 2009-11-05 2013-03-06 Biocon Ltd NEW METHOD FOR THE PRODUCTION OF PROSTAGLANDINES AND INTERMEDIATE PRODUCTS THEREOF
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US9248135B2 (en) * 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
WO2016061370A1 (en) 2016-04-21
US10016441B2 (en) 2018-07-10
RU2017116230A (ru) 2018-11-15
JP6830991B2 (ja) 2021-02-17
CN107106573A (zh) 2017-08-29
BR112017007095A2 (pt) 2017-12-26
CN112022856A (zh) 2020-12-04
MX2020012012A (es) 2022-04-19
US20170239268A1 (en) 2017-08-24
AR102283A1 (es) 2017-02-15
BR112017007095B1 (pt) 2023-03-14
JP6654757B2 (ja) 2020-02-26
MX2017004809A (es) 2017-07-26
MX2019011925A (es) 2019-11-18
RU2712221C2 (ru) 2020-01-27
AU2015332447B2 (en) 2018-10-25
US20160108012A1 (en) 2016-04-21
JP2017531018A (ja) 2017-10-19
AU2015332447A1 (en) 2017-04-27
CA2964364A1 (en) 2016-04-21
KR20170066427A (ko) 2017-06-14
RU2017116230A3 (es) 2019-05-22
MX2020012011A (es) 2022-04-19
JP2020023556A (ja) 2020-02-13
US9604949B2 (en) 2017-03-28
EP3206693A1 (en) 2017-08-23
EP3206693B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MY171920A (en) Prevention and treatment of ocular conditions
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MY186271A (en) Ophthalmic compositions and methods of use therefor
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
NZ746468A (en) Methods of treating ocular conditions
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
PH12020550550A1 (en) Sustained-release implants for lowering intraocular pressure with extended duration of effect
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP3691654A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
EP3709982A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASES
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
TW201613596A (en) Ophthalmic suspension preparation
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
GR1008527B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον βιματοπροστη